Dr. Omid Farokhzad, Chair, CEO and Founder of Seer, discusses how Seer’s cutting edge work with protein and proteomics is removing technological barriers and providing scientists with better tools to make breakthroughs than ever before.
BioReport Podcast: CEO Omid Farokhzad explains why, although great progress has been made in understanding the human genome, the human proteome remains relatively unexplored.
Motley Fool: interview with CEO Omid Farokhzad on the future of proteomics.
Benzinga: interview with CEO Omid Farokhzad on the importance of proteomics
Seer signs agreement with Sciex: Seer and SCIEX have signed a commercial agreement to provide end to end unbiased proteomics solutions.
Seer adds board members: Seer appoints Deep Nishar and Mostafa Ronaghi, Ph.D. to its Board of Directors
Seer and Bruker Sign Commercial Agreement to Expand Market for Unbiased, Deep Proteomics
Seer Signs Commercial Agreement to Provide Complete End-to-End Solution for Unbiased, Deep, Rapid and Large-Scale Proteomics
Seer announced the pricing of its initial public offering of 9,210,527 shares of Class A common stock.
Seer Appoints Catherine Friedman to its Board of Directors